Matricelf

25/06/2025

Matricelf to Present at 2025 Spinal Cord Injury Conference https://scisymposium.com/ Matricelf Ltd. (TASE: MTLF), a biotechnology company pioneering autologous regenerative implants for spinal cord injury (SCI), is pleased to announce its upcoming presentation at a leading international SCI conferen...

03/06/2024

🐭🐭🐭🐭🐭
Matricelf is excited to update that today a rat pilot study started, aimed at a preliminary examination of the efficacy of engineered human neural tissue for the treatment of spinal cord injury. This is a preliminary trial before conducting a definitive rats efficacy study, in accordance with the development plan presented by the company to the FDA as part of a Pre-IND.

The efficacy study, that will include 61 rats, will examine 2 test groups vs. a control sham group via a number of behavioral tests. Immunodeficient rats will be used in the study, in order to simulate autologous treatment; whereas a contusion spinal cord injury will simulate common injuries in humans (such as car accidents, falls, etc.).

Starting the pilot study is an additional step towards the fulfillment of our vision - to provide an innovative therapeutic solution for patients suffering from spinal cord injuries. The animal pilot study is a result of professional and intensive development work that includes the use of advanced tissue engineering and cellular therapy methods. The development team continues its thorough work to develop an innovative tissue engineering technology that will meet the strict regulatory requirements on the way to a clinical trial in humans.
🐭🐭🐭🐭🐭

מטריסלף שמחה לעדכן שהחלה היום ניסוי פיילוט בחולדות שמטרתו בחינה מקדימה של יעילות רקמה עצבית אנושית מהונדסת לטיפול בפציעות חוט שדרה. מדובר בניסוי מקדים טרם ביצוע ניסוי יעילות מקיף וזאת בהתאם לתוכנית הפיתוח שהציגה החברה ל-FDA במסגרת Pre-IND.
במסגרת הניסוי, אשר יכלול 61 חולדות (חיית המודל המקובלת לניסויים מסוג זה), ייבחנו 2 קבוצות טיפול מול קבוצת ביקורת (ללא טיפול) וייבדקו מספר מדדים התנהגותיים מקובלים לשם הערכת יעילות הטיפול. הניסוי יכלול חולדות בעלות מערכת חיסונית מוחלשת על מנת לאפשר סימולציה של טיפול אוטולוגי (עצמי) וכן פציעת מעיכה (contusion) המדמה פציעות שכיחות בבני אדם (כמו במקרים של תאונות דרכים, נפילות וכו').
התחלת ניסוי הפיילוט מהווה עוד צעד לקראת הגשמת החזון שלנו - לספק פתרון רפואי חדשני לאנשים הסובלים מפציעות חוט שדרה הגורמות לשיתוק. ניסוי הפיילוט בחיות הינו תוצאה של עבודת פיתוח מקצועית ומאומצת הכוללת שימוש בשיטות מתקדמות להנדסת רקמות ותרפיה תאית בשאיפה להביא מזור לפצועי חוט שדרה רבים. צוות הפיתוח ממשיך בעבודתו היסודית לפיתוח טכנולוגיה חדשנית להנדסת רקמות שתדע לעמוד בדרישות רגולטוריות מחמירות בדרך לניסוי קליני בבני אדם.
🐭🐭🐭🐭🐭

19/11/2023

Matricelf is proud of Tamar Harel Adar, Matricelf VP R&D, that presented the company's technology at the honored Personalized RegenMed forum in Cambridge, US, organized by Cellino. Now, more than ever, the power of science and humanity unites the world.

14/09/2023

We are happy to share that Dr. Ruchi Sharma joined the scientific advisory committee of Matricelf. Dr. Sharma is a researcher at the National Eye Institute of the National Institute of Health (NIH) in the USA and an expert in induced pluripotent stem cells (iPSCs) manufacturing for clinical use. As part of her role, Ruchi was involved in the development of differentiation processes of stem cells to create an autologous treatment for Age-related Macular Degeneration (AMD), which is currently being examined as part of a clinical trial in the USA. This clinical trial, which involves iPSCs-based technology, was the first to be approved by the FDA. Dr. Sharma has published many articles in the field and has a deep understanding and extensive experience in developing translational technologies. Dr. Sharma's joining the SAB will contribute to the company in promoting the development program as well as future clinical manufacturing.

עברית בתגובות

26/07/2023

עברית בתגובה הראשונה

We are happy to update that we have successfully completed experiments showing electrical functionality of the neural tissue implants that the company engineers for the treatment of spinal cord injuries.
As part of the experiments, electrical conductivity of the engineered tissue was tested under laboratory conditions on Multi-Electrode Array (MEA) chips, which monitor parameters of electrical activity over time.
The results indicate the formation of spontaneous electrical activity which increases and expands over several days, including synchronized neural signaling between different areas of the tissue. This indicates the formation of functioning connections (synapses) between neurons within the tissue which are an expression of its maturation into functioning neural tissue.

The spinal cord is an integral part of the central nervous system, and its main function is to communicate between the brain and the limbs by sending electrical signals that mediate sensor and motor activity. In cases of spinal cord injuries, these functions may be damaged and even lead to paralysis.
Demonstration of electrical activity within the engineered tissue indicates physiological integration potential of the implant with the patient's spinal cord tissue, which may lead to regeneration of the injured spinal cord.
These results are an important step in basing the potential of treating spinal cord injuries in humans using Matricelf implants.

16/07/2023

And... we're back!

After a construction period, our website is on the air again.

Come visit us :)

Regenerating the Future of Medicine - Personalized platform for autologous regenerative medicine

12/07/2023

We are happy to share that we have printed for the first time a three-dimensional (3D) structure of a human ear using the unique support medium that was produced in our laboratory. This innovative technology is based on a patent held by the company that enables the 3D bioprinting of volumetric structures of cells and extracellular components, to create living organs and tissues, which constitute most of the body's organs. The uniqueness of the technology is based on nanoparticles, which stabilize the printed biological structure, and allows printing with high resolution for maximum accuracy. The support medium was developed in such a way that it can provide both accuracy and quality of printing as well as assure safety that will allow printing of organs and tissues and their implantation in humans. The support medium produced by the company successfully met the requirements of transparency, printing accuracy, supporting the printed model as well as safe extraction of the model following printing.

Matricelf estimates that this technology constitutes a complementary aspect to the company's ability to print complex and functional tissues in the future and position it at the forefront of the 3D biological printing field.
Alon Sinai, CEO: "In recent years there has been a tremendous global effort to promote and develop advanced technologies in the field of tissue and organ bioprinting. This field is gaining momentum in the world of medicine and has the potential to answer the shortage of organs for transplantation. This is a huge economic market that attracts global pharma, engineering, and biotech companies to continue developing innovative and groundbreaking solutions. Matricelf's significant progress positions her as a leading player in the field."

עברית בתגובה הראשונה

18/06/2023

מטריסלף גאה בפרופ' טל דביר, המדען הראשי של החברה, על זכייתו בפרס דה וינצ'י היוקרתי על הישגיו בתחום הרפואה הרגנרטיבית ועל פיתוח טכנולוגיות להדפסת איברים. פרס דה וינצ'י הבינלאומי מוענק אחת לשנה על הישגים יוצאי דופן בתחומי המדעים, הטכנולוגיה, הספרות והאומנויות.
לצידו של פרופ' דביר זכו השנה גם חתני פרס נובל בתחום הרפואה, פרופ' שיניה ימאנאקה מאוניברסיטת טוקיו ביפן ופרופ' גרג לאונרד סמנזה מבית הספר לרפואה של אוניברסיטת ג'ונס הופקינס בארה"ב.
כל הכבוד!

Matricelf is proud of Prof. Tal Dvir, the company's chief scientist, for receiving the prestigious Da Vinci Award for his achievements in the field of regenerative medicine and for the development of organ bioprinting technologies. The International Da Vinci prize is annually awarded for outstanding achievements in the fields of sciences, technology, literature and the arts.
Together with Prof. Dvir, this year's winners include Nobel Prize laureates in the field of medicine, Prof. Shinya Yamanaka from the University of Tokyo in Japan and Prof. Gregg Leonard Semenza from the Johns Hopkins University School of Medicine in the USA.
Well done!

01/06/2023

We're delighted to announce that Matricelf has received Israeli Ministry of Health approval for the conceptual design of our GMP production facility, marking an important milestone in our journey. This facility which includes designated clean rooms, will enable the production of autologous neural tissue implants for the treatment of spinal cord injury as part of a future clinical trial. With a focus on advanced cellular therapies and adherence to sterile products standardization, we're aspired to revolutionizing the treatment of spinal cord injuries.
This approval allows us to progress towards detailed planning and construction that would grant us independent capacity for the entire production chain. The conceptual planning, executed under the professional guidance of the engineering and validation department at Gsap, ensures a state-of-the-art facility.

19/05/2023

Matricelf is happy to update that we successfully completed the model establishment for the safety examination of neural human implants intended for the treatment of spinal cord injuries. As part of model development, the ability to transplant the implants in the cervical region of the spinal cord was examined in immunodeficient rats ("n**e" rats) which maintained their neural function, as required.

This model will allow an examination that can confirm the safety of the implants, specifically an implantation in the cervical, dorsal and lumbar areas of a human spinal cord. In addition, the use of "n**e" rats enables the simulation of autologous (self) treatment in humans. The model complies with the regulatory requirements and was presented to the FDA as part of Pre-IND submission on which the company received feedback confirming the parameters included in the model. The establishment of the model was done with a leading CRO (Research Contract Organization) in Israel, with a proven ability to plan and perform GLP (Laboratory Good Practice) level experiments, as required for the authorization to conduct human studies.

Dr. Tamar Harel Adar, VP RD: "The company has been operating in several parallel channels in the recent months, in order to promote the development plan, according to the planned schedule. The completion of the establishment of this model enables the implementation of extensive safety experiments in animals to confirm the safety of the implants we develop. Like other models we have developed to prove the effectiveness and safety of the treatment, this model also corresponds with the feedback the company received from the FDA as part of Pre-IND submission".